Innocan Pharma's Compassionate Care Treatment for Dogs A Case Report Published in Frontiers in Veterinary Science
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - April 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the publication of a case report regarding its compassionate care liposomal-CBD formulation (Innocan's LPT platform) (the "Treatment"). The Treatment was administered to a 14-year-old dog suffering from severe cervical pain, hip and elbow osteoarthritis and testicular neoplasia. It was reported that the Treatment resulted in decreased pain and improved mobility. The journal, Frontiers in Veterinary Science, is a global, peer-reviewed, open access publication that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy.
Innocan Pharma's Compassionate Care Treatment for Dogs